China approves first oral GLP-1 weight-loss pill

China has approved its first orally administered GLP-1 weight-loss drug, permitting Eli Lilly to sell its orforglipron pill in a market where 630 million adults could be overweight or obese by 2050.

Q&A: Rethinking immunity beyond 'strong' and 'weak'

Melinda Fagan, professor in the Department of Philosophy at the University of Utah, where she holds the Sterling M. McMurrin Chair, proposed in a recent paper a new approach to understanding immunity for both experts and ...

page 13 from 38